Hospital potentially avoidable readmissions in general internal medicine: elaboration of a predictive score

Anne-Laure Blanc1,2,3,4, Thierry Fumeaux2, Jérôme Stirmann1, Marc Carpentier1, Aimad Ourhamoune1, Jules Desmeules1, Pierre Chopard1, Arnaud Perrier1, Nicolas Schaad1, Pascal Bonnabry1,2,4

1 University Hospitals of Geneva, Switzerland, 2 Groupement hospitalier de l’ouest-lémanique (GHOL), Nyon, Switzerland, 3 Pharmacie Interhospitalière de la Côte, Morges, Switzerland, 4 School of pharmaceutical sciences, University of Geneva, University of Lausanne, Geneva, Switzerland

Background & objective

Patients at risk of readmission should be identified early during hospital stay, in order to benefit from specific interventions. The aim of this study was to:

- characterize patients readmitted in two Swiss hospitals,
- include a specific focus on medication profile,
- create a predictive tool of hospital potentially avoidable readmissions.

Method

This retrospective study included all patients identified by SQLape algorithm as readmitted within 30 days in 2011 in general medicine wards in HUG and GHOL. Control patients, not identified by SQLape as readmitted, were matched on age and sex.

Factors associated with potentially preventable readmission were identified with a multivariate logistic regression. Variables of interest were demographic data, diagnoses, lab results and medications at discharge. A predictive score was developed using a regression coefficient-based scoring method.

Results

This table summarizes the results of the study:

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
<td>7</td>
</tr>
<tr>
<td>Myocardial Infarction or Ischemic cardiopathy</td>
<td>5</td>
</tr>
<tr>
<td>Previous admission within six months</td>
<td>8</td>
</tr>
<tr>
<td>Potassium &gt; 5.5 mmol/L</td>
<td>9</td>
</tr>
<tr>
<td>Oncological comorbidities</td>
<td>4</td>
</tr>
<tr>
<td>COPD*</td>
<td>5</td>
</tr>
<tr>
<td>Cognitive comorbidities*</td>
<td>5</td>
</tr>
<tr>
<td>RAA Drugs : ACE inh/Angiotensin II antag.</td>
<td>-7</td>
</tr>
<tr>
<td>Anemia*</td>
<td>2</td>
</tr>
<tr>
<td>Length of Stay &gt; 14 days</td>
<td>7</td>
</tr>
</tbody>
</table>

* Non significative but predictive covariates

The table below shows the multivariate analysis:

<table>
<thead>
<tr>
<th>Demographic risk factors</th>
<th>p value</th>
<th>Adjusted OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 14 d.</td>
<td></td>
<td>1.16</td>
<td>0.81 - 1.66</td>
</tr>
<tr>
<td>&gt; 14 d.</td>
<td>&lt;0.01</td>
<td>2.12</td>
<td>1.35 - 3.33</td>
</tr>
<tr>
<td>Previous admission within 6 month</td>
<td>&lt;0.01</td>
<td>2.11</td>
<td>1.53 - 2.90</td>
</tr>
</tbody>
</table>

Comorbidities

- Anemia: 0.16 (OR 1.28, 95% CI 0.91 - 1.79)
- Hypertension: 0.84 (OR 0.96, 95% CI 0.66 - 1.39)
- Arrhythmias: 0.78 (OR 1.06, 95% CI 0.70 - 1.58)
- Liver abnormalities: 0.35 (OR 1.25, 95% CI 0.78 - 1.98)
- COPD: 0.10 (OR 1.48, 95% CI 0.93 - 2.35)
- Dementia: 0.07 (OR 1.69, 95% CI 0.95 - 2.98)
- Diabetes: 0.71 (OR 1.11, 95% CI 0.64 - 1.91)

Heart failure

- Renal impairment: 0.24 (OR 0.82, 95% CI 0.47 - 1.39)
- Chronic: 1.24 (OR 0.80, 95% CI 0.59 - 1.30)
- Acute on chronic: 0.70 (OR 0.40, 95% CI 0.18 - 0.90)

Malignancy tumor

- Myocardial infarction or ischemic cardiopathy: 0.04 (OR 0.72, 95% CI 1.09 - 2.75)

Laboratory results

- Hyperkalémia (K > 5.5mmol/L): 0.01 (OR 2.56, 95% CI 1.24 - 5.41)
- Hypertension (Na > 145mmol/L): 0.26 (OR 1.55, 95% CI 0.72 - 3.27)
- INR > 3.5 with AVK drugs: 0.86 (OR 1.07, 95% CI 0.51 - 2.17)

Medication risk factors

- Anti-platelet drugs: 0.48 (OR 0.83, 95% CI 0.50 - 1.38)
- Anticoagulant: 0.73 (OR 1.08, 95% CI 0.71 - 1.64)
- Beta-blockers: 0.87 (OR 1.04, 95% CI 0.69 - 1.56)
- Benzodiazepine: 0.13 (OR 1.30, 95% CI 0.93 - 1.83)
- Diuretics: 0.59 (OR 0.88, 95% CI 0.56 - 1.40)
- Glucose lowering drugs: 0.55 (OR 1.20, 95% CI 0.66 - 2.22)
- Other antiabetic drugs: 0.28 (OR 0.69, 95% CI 0.35 - 1.34)
- Opioids: 0.38 (OR 1.18, 95% CI 0.81 - 1.73)
- ACE inh. / angiotensin II antag.: <0.01 (OR 0.51, 95% CI 0.34 - 0.77)

Table of final multivariate analysis

- Nb of severe drug-drug interactions: 0.55 (OR 1.27, 95% CI 0.74 - 2.15)

Discrimination power

The C-statistic shows the discrimination power of the model:

C-statistic: Score : AUC = 0.714 (95%CI 0.680-0.749)

Conclusion

This retrospective study identified several factors significantly associated with potentially avoidable readmissions and routinely available during hospital stay. Based on these results, a predictive score has been developed and an internal validation will be performed in order to confirm these results.

Limitations

- Retrospective study
- Only two hospital involved in the study
- Potentially avoidable readmission defined by SQLape algorithm
- Patient transferred to long term care and patients readmitted outside GHOL and HUG: not included

Contact: anne-laure.blanc@hcuge.ch